+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030- Product Image
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030- Product Image
Sale

Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010725
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cardiovascular Therapeutics Market grew from USD 50.71 billion in 2024 to USD 54.58 billion in 2025. It is expected to continue growing at a CAGR of 7.57%, reaching USD 78.57 billion by 2030.

Setting the stage for cardiovascular therapeutics innovation

Cardiovascular disease remains the leading cause of mortality worldwide, exerting profound pressure on healthcare systems and innovation pipelines alike. As populations age and risk factors such as diabetes and obesity rise, the demand for advanced therapeutic solutions has never been more urgent. This executive summary offers a concise yet comprehensive overview of the dynamics shaping the cardiovascular therapeutics market and highlights the critical trends forging its next phase of growth.

Innovation in pharmacology and medical devices is converging with breakthroughs in digital health to create an ecosystem poised for transformative impact. From next-generation anticoagulants to implantable monitoring systems, the array of emerging interventions underscores the strategic importance of agility, collaboration, and patient-centric design. In such a rapidly evolving environment, industry participants must align development priorities with real-world needs, regulatory expectations, and evolving reimbursement models.

This document synthesizes key insights-ranging from macroeconomic shifts to granular segmentation analysis-to equip stakeholders with the knowledge required to navigate complexity, identify growth levers, and build robust, future-proof strategies.

Transformational forces reshaping the cardiovascular landscape

The cardiovascular space is being reshaped by converging forces that challenge legacy models and unlock new avenues for patient care. Regulatory frameworks are adapting to accelerated approval pathways and real-world evidence requirements, enabling faster market entry for breakthrough therapies. At the same time, advances in genomics and biomarker discovery are laying the groundwork for precision medicine, allowing clinicians to tailor interventions according to individual risk profiles and disease phenotypes.

Digital health tools are proliferating across the continuum of care, from wearable sensors that continuously monitor blood pressure and heart rhythm to telemedicine platforms facilitating virtual consultations. These innovations are empowering patients to participate actively in their treatment journeys while generating rich data streams that inform product development and outcome assessment. Collaboration between pharmaceutical companies, technology firms, and payers is becoming essential, as each stakeholder brings complementary capabilities to create integrated solutions that address adherence, affordability, and access.

Looking ahead, the industry’s ability to harness artificial intelligence and machine learning for predictive analytics promises to revolutionize early detection and intervention strategies. By aligning these technological breakthroughs with robust clinical evidence and stakeholder engagement, the market is poised for sustained expansion and improved patient outcomes.

Assessing the 2025 tariff landscape in the United States

In 2025, newly implemented tariff measures in the United States have introduced notable cost pressures across pharmaceutical and device supply chains. Import duties on active pharmaceutical ingredients and finished goods have elevated production expenses, compelling manufacturers to reassess sourcing strategies. Raw material suppliers and contract development organizations are adjusting their pricing models to pass through incremental costs, which may influence the competitive dynamics between branded and generic offerings.

Device makers, particularly those relying on specialized components sourced internationally, are experiencing extended lead times and logistical complexities. These challenges have spurred nearshoring initiatives aimed at securing domestic manufacturing capacity, while some players are diverting procurement to alternative low-tariff regions. In parallel, greater emphasis on vertical integration is emerging as companies seek to internalize key supply chain segments and mitigate exposure to external shocks.

Although the immediate financial impact appears manageable for large multinational corporations with diversified portfolios, smaller innovators and emerging contract manufacturers face heightened risk. To maintain profitability, portfolio optimization and strategic partnerships will be critical. Companies that anticipate evolving trade policies and invest in resilient supply chain infrastructures will be better positioned to sustain growth and deliver uninterrupted patient access.

Unveiling the layers of market segmentation

A nuanced understanding of market segmentation reveals where therapeutic opportunities intersect with clinical need and commercial viability. The therapy type classification spans antiarrhythmics, anticoagulants, antihypertensives, and lipid lowering agents. Within antiarrhythmics, subcategories include Class I through Class IV agents, with Class III further delineated into Amiodarone, Dofetilide, and Sotalol. Anticoagulant therapies bifurcate into Vitamin K antagonists and non-vitamin K oral anticoagulants, the latter encompassing Apixaban, Dabigatran, and Rivaroxaban. Antihypertensive treatments range from ACE inhibitors and ARBs to beta blockers, calcium channel blockers, diuretics, and renin inhibitors, while lipid management relies on Ezetimibe, fibrates, niacin, PCSK9 inhibitors, and statins.

In parallel, segmentation by end user covers ambulatory surgical centers, clinics, home care settings, and hospitals, each reflecting distinct procurement cycles and utilization patterns. Applications include arrhythmia management, coronary artery disease interventions, hyperlipidemia control, hypertension treatment, and thromboembolic disorder prevention. Delivery modes encompass implantable systems, injectable formulations, oral therapies, and transdermal platforms, illustrating the breadth of product innovation and patient experience considerations. By intersecting these four segmentation dimensions, stakeholders can pinpoint high-value niches, tailor go-to-market strategies, and anticipate evolving demand based on treatment settings, disease prevalence, and technological adoption.

Regional dynamics driving market trajectories

Regional ecosystems exhibit unique characteristics that influence both market performance and strategic priorities. In the Americas, robust healthcare infrastructure, mature reimbursement pathways, and high patient awareness drive significant demand for premium therapeutic solutions, particularly in chronic disease management. Government initiatives that expand insurance coverage and incentivize preventive care continue to bolster adoption of advanced cardiovascular products.

Europe, the Middle East & Africa present a mosaic of regulatory harmonization efforts and varying levels of healthcare investment. While Western Europe benefits from established clinical networks and progressive reimbursement models, emerging markets in Eastern Europe, the Gulf Cooperation Council, and Africa are characterized by rising healthcare expenditures and nascent product adoption curves. Tailored engagement with local authorities and adaptation of pricing strategies are essential to penetrate these diverse subregions effectively.

Asia-Pacific remains a high-growth frontier, driven by demographic shifts, urbanization, and expanding medical infrastructure. Nations such as China and India are scaling up cardiovascular disease screening programs and investing in domestic production capabilities. Meanwhile, smaller markets in Southeast Asia and Oceania are increasingly receptive to digital health solutions that alleviate provider shortages and enhance patient monitoring.

Competitive landscape and leading innovators

The competitive environment in cardiovascular therapeutics is defined by established pharmaceutical leaders, specialized device manufacturers, and agile biotech entrants. Major industry players have secured their portfolios through both internal R&D and strategic acquisitions, focusing on blockbuster anticoagulants, first-in-class antihypertensives, and cutting-edge interventional devices. Simultaneously, emerging companies leverage nimble organizational structures to accelerate clinical trials and align development programs with unmet clinical needs.

Partnerships between large and small entities accelerate innovation, bringing novel mechanisms of action from lab to clinic. Co-development agreements with technology firms enable integration of digital monitoring tools into therapeutic regimens, enhancing real-world data capture and patient engagement. Intellectual property landscapes remain fiercely contested, with patent expirations prompting generics and biosimilars to enter the fray, intensifying price competition.

Navigating this landscape requires a sharp focus on pipeline replenishment, lifecycle management, and geographic expansion. Companies that balance therapeutic breadth with specialized expertise-while maintaining agility in responding to regulatory changes-will establish sustainable competitive advantages.

Strategic imperatives for industry leaders

Industry leaders must adopt a multifaceted strategy to capitalize on emerging opportunities and mitigate evolving risks. First, investing in digital health ecosystems-from remote monitoring devices to AI-driven diagnostic platforms-will enhance patient engagement and differentiate product offerings. Second, diversifying supply chains through nearshoring, strategic alliances, and vertical integration will reinforce resilience against trade disruptions and raw material shortages.

Third, embracing precision medicine approaches by leveraging biomarkers and genetic profiling can unlock premium pricing and improve clinical outcomes. Collaborations with diagnostic companies and academic consortia will accelerate these initiatives. Fourth, engaging with payers early in development to co-design value propositions grounded in real-world evidence will facilitate smoother reimbursement pathways and broader market access. Fifth, exploring innovative pricing models, including outcomes-based contracts and subscription frameworks for durable devices, can align stakeholder incentives and drive adoption.

Finally, fostering a culture of continuous innovation and organizational agility will empower teams to respond swiftly to regulatory shifts, competitive threats, and evolving patient needs. By embedding these strategic imperatives into core operations, companies can achieve sustainable growth and deliver meaningful impact to patients worldwide.

Methodological framework underpinning the analysis

This analysis draws on a rigorous research framework combining primary and secondary data sources to ensure robust, actionable insights. In-depth interviews with key opinion leaders, industry executives, and healthcare providers provided qualitative context around unmet needs, clinical adoption barriers, and innovation trajectories. A comprehensive review of regulatory filings, clinical trial databases, patent registries, and published literature supported triangulation of market trends and competitive positioning.

Secondary data collection included analysis of financial disclosures, annual reports, and investor presentations to assess company strategies and performance metrics. Regional market sizing and payer landscape assessments leveraged government health statistics, reimbursement guidelines, and epidemiological data. Quantitative modeling techniques were applied to identify demand drivers and correlate segmentation factors with growth patterns.

All findings underwent peer review by subject-matter experts to validate assumptions and ensure alignment with current industry conditions. This methodological approach delivers a transparent, credible foundation for the strategic recommendations presented herein.

Synthesizing insights to chart future growth

This executive summary captures the dynamic interplay between clinical innovation, market forces, and regulatory landscapes shaping cardiovascular therapeutics. By synthesizing segmentation insights, regional characteristics, competitive dynamics, and tariff impacts, stakeholders gain a holistic understanding of the key drivers and challenges in this high-stakes arena. The strategic imperatives outlined herein equip decision-makers with a blueprint for prioritizing investments, optimizing portfolios, and accelerating patient-centric advancements.

As the market continues to evolve, ongoing vigilance, adaptive planning, and stakeholder collaboration will be essential. Embracing digital health integration, precision medicine, and resilient supply chains will position organizations to deliver superior clinical value and achieve sustainable commercial success. Ultimately, the capacity to translate cutting-edge science into accessible, affordable solutions will drive the next wave of growth in cardiovascular care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Antiarrhythmics
      • Class I
      • Class Ii
      • Class Iii
        • Amiodarone
        • Dofetilide
        • Sotalol
      • Class Iv
    • Anticoagulants
      • Nonvitamin K Oral Anticoagulants
        • Apixaban
        • Dabigatran
        • Rivaroxaban
      • Vitamin K Antagonists
    • Antihypertensives
      • Ace Inhibitors
      • Arbs
      • Beta Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Renin Inhibitors
    • Lipid Lowering Agents
      • Ezetimibe
      • Fibrates
      • Niacin
      • Pcsk9 Inhibitors
      • Statins
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Home Care
    • Hospitals
  • Application
    • Arrhythmia
    • Coronary Artery Disease
    • Hyperlipidemia
    • Hypertension
    • Thromboembolic Disorders
  • Delivery Mode
    • Implantable
    • Injectable
    • Oral
    • Transdermal
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
5.1.1.2. Technological advancements and innovation in cardiovascular therapeutics fostering market growth
5.1.1.3. Rising healthcare expenditure and supportive government policies boosting market expansion
5.1.1.4. Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
5.1.2. Restraints
5.1.2.1. Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
5.1.2.2. Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
5.1.3. Opportunities
5.1.3.1. Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
5.1.3.2. Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
5.1.3.3. Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
5.1.4. Challenges
5.1.4.1. Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
5.1.4.2. Financial sustainability and profitability challenges impacting investments in cardiovascular research and development
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cardiovascular Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Antihypertensive Drugs
6.2.1. Beta Blockers
6.2.2. Calcium Channel Blockers
6.2.3. Renin-Angiotensin System Inhibitors
6.2.3.1. ACE Inhibitors
6.2.3.2. Angiotensin II Receptor Blockers
6.3. Antithrombotic Drugs
6.3.1. Anticoagulants
6.3.2. Antiplatelet Agents
6.3.3. Thrombolytics
6.4. Lipid-Lowering Drugs
6.4.1. Fibrates
6.4.2. Niacin
6.4.3. Statins
7. Cardiovascular Therapeutics Market, by Indication
7.1. Introduction
7.2. Angina Pectoris
7.3. Heart Failure
7.4. Hyperlipidemia
7.5. Hypertension
7.6. Myocardial Infarction
7.7. Stroke
8. Cardiovascular Therapeutics Market, by Patient Demographics
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Cardiovascular Therapeutics Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Emergency Services
9.4. Homecare Settings
9.5. Hospitals
10. Cardiovascular Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.4. Transdermal
11. Cardiovascular Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Cardiovascular Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Cardiovascular Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Cardiovascular Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CARDIOVASCULAR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. CARDIOVASCULAR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. CARDIOVASCULAR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CARDIOVASCULAR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CARDIOVASCULAR THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY NIACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 91. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 92. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 97. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 146. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 148. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 149. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 151. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 154. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 157. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 159. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 160. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 165. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 181. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 182. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 184. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 187. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 253. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 264. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 282. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 284. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 287. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 298. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 301. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 303. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MIL

Companies Mentioned

The companies profiled in this Cardiovascular Therapeutics market report include:
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim GmbH

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 54.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 78.57 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 118 Pages
  • Global
From
Statins Market by Product Type, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Statins Market by Product Type, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Etofibrate Market by Distribution Channel, Product Type, End User, Strength - Global Forecast to 2030 - Product Image

Etofibrate Market by Distribution Channel, Product Type, End User, Strength - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Acute Coronary Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Acute Coronary Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 237 Pages
  • Global
From
Myocardial Infarction Market Report 2025 - Product Image

Myocardial Infarction Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Cardiovascular Drugs Market

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.